Introduction
The National Control Laboratories (NCLs) play an essential role in the quality assurance for vaccines, blood products and other biological medical products. NCL establish and manage national reference standards, develop and identify models of standard methodology, they review manufacturers' data, and perform independent quality control testing.
Regulatory harmonization through standardization of quality assessment and testing methodology is crucially important for improving access on a regional and global This report provides highlights of the presentations along with summaries of the discussions that followed, together with conclusions and recommendations for each of the key areas reviewed at this conference.
Participants
The 2-day meeting was organized by the National Institute Dr. Ochiai stated that NIID is discussing the introduction of a graduated risk-based approach to lot release testing to achieve a more appropriate and efficient use of limited resources, whilst ensuring high quality vaccine.
Session B: Quality control testing methods for Japanese encephalitis vaccines
Dr. Chang Kweng Lim (NIID, Japan) presented an overview of Japanese encephalitis (JE), the quality control for JE vaccines, and the national epidemiological surveillance in Japan. He explained that no specific treatment for JE exists;
and vaccination is an effective means of prevention [2] . JE outbreaks in Japan up to 1965, frequently produced 3,000 to 5,000 cases.
The Nakayama strain of the JE virus was first isolated from Dr. Raut also highlighted assay discrepancy issues when using different chromogenic assay kits, and these issues were investigated in a European Collaborative Study carried out by the European Directorate for the Quality of Medicines (EDQM).
The study found significant differences in FVIII potency observed and indicated that it was likely to be due to the different rates of FX activation of individual kits.
In addition, in his second presentation, he described other collaborative studies, including a field study to investigate, "assay variability in potency assessment of recombinant FVIII products and a FVIII inhibitor using the South Mimms Inhibitor Assay," both of which highlighted discrepancy issues relating to use of FVIII deficient plasma. 
Progress and key findings of WPR NCL agenda
Regarding the progress of a collaborative study on antivenom references using LD50 and MHD assays, a proposal was raised by NIFDS and supported by the participating NCLs, at the first NCL meeting in 2016 [10] . Regarding the plans for a collaborative study on Factor XIa in plasma-derived products, NIFDS described a feasibility study on the selection of study materials and test methods. In the collaborative study proposal session, establishment for the first national reference standard 
Conflicts of Interest
The authors have disclosed no potential conflicts of interest.
